miRNA as diagnostic and prognostic biomarkers for patients with prostate cancer

Wei GUO,Ci ZHANG,Zhenlei SHI
DOI: https://doi.org/10.3969/j.issn.1009-6469.2017.09.001
2017-01-01
Abstract:Current prostate cancer (PCa) diagnosis is based on the serum prostate-specific antigen biomarker and digital rectal examination.However,these methods are limited by a low predictive value and a high risk of mistaken results.In recent years,new promising biomarkers such as prostate cancer antigen 3 (PCa-3) and TMPRSS2-ETS fusion genes have been used in clinical diagnosis.However,the search of new biomarkers that could be used for PCa diagnosis and prognosis is still needed.Recent studies have demonstrated that the aberrant expression of microRNA (miRNA),small non-coding RNA that negatively regulate gene expression,is related with the development of several cancers,including PCa.Since miRNA serve as phenotypic signatures of different cancers,they appear as potential diagnostic,prognostic and therapeutic tools.Here,we review the current knowledge of miRNA expression patterns in PCa and their role in PCa prognosis and therapeutics.
What problem does this paper attempt to address?